The conversation with Stephen Hahn, MD, addressed challenges associated with hydroxychloroquine access during the COVID-19 public health emergency and handling patient concerns about potential cardiac side effects.
Guselkumab Approved for PsA
Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…
FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
In June, the FDA approved secukinumab to treat non-radiographic axial spondyloarthritis after data from a clinical trial demonstrated its efficacy…
FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis
HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…
FDA Approves Canakinumab for Adult-Onset Still’s Disease
Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
FDA Approves Celecoxib in an Oral Solution
The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…
2 Pediatric Indications Sought for Golimumab
The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market
Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…
U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19
(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…
FDA Cautions Slower Drug Review Activity Due to Staff Reallocation for COVID-19
(Reuters)—On April 16, the U.S. Food & Drug Administration (FDA) cautioned that with a lot of its staff allocated to the coronavirus crisis, it may not be able to sustain its current level of timely reviews and approvals of marketing applications. FDA says it was working to ensure that the drug programs continue to see…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »